MELFIAT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MELFIAT (MELFIAT).
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
| Metabolism | Melfiat is extensively metabolized in the liver via N-demethylation and aromatic hydroxylation, primarily by CYP3A4 and other cytochrome P450 enzymes. |
| Excretion | Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces. |
| Half-life | Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment. |
| Protein binding | 85-90% bound to serum albumin. |
| Volume of Distribution | 4-6 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is 60-75% due to first-pass metabolism. |
| Onset of Action | Oral: 1-2 hours; clinical effect on appetite suppression begins within 2-3 hours. |
| Duration of Action | Approximately 8-12 hours after a single oral dose, supporting once-daily dosing. |
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
| Dosage form | TABLET |
| Renal impairment | Avoid use in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-59 mL/min), initiate at 75 mg daily and monitor. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate impairment (Child-Pugh A or B), use with caution; maximum 75 mg daily. |
| Pediatric use | Not recommended in children under 12 years due to lack of safety data. |
| Geriatric use | Start at 75 mg daily; elderly patients may be more sensitive to central nervous system stimulation. Avoid in frail patients or those with cardiovascular disease. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MELFIAT (MELFIAT).
| Breastfeeding | Mefenamic acid is excreted into breast milk in small amounts (M/P ratio not established). Due to potential adverse effects on the infant's renal function and cardiovascular system, breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Pregnancy Category X. Melfiat (mefenamic acid) is contraindicated in all trimesters. First trimester: associated with increased risk of spontaneous abortion and cardiac malformations. Second and third trimesters: causes premature closure of the ductus arteriosus, oligohydramnios, and fetal renal impairment. Avoid in all trimesters. |
■ FDA Black Box Warning
None
| Serious Effects |
["History of cardiovascular disease (e.g., coronary artery disease, arrhythmias)","Severe hypertension","Hyperthyroidism","Glaucoma","History of drug abuse","Concomitant use or within 14 days of MAO inhibitors","Pregnancy and lactation"]
| Precautions | ["Risk of primary pulmonary hypertension","Risk of valvular heart disease associated with serotonergic agents","Potential for abuse and dependence, especially in patients with history of substance abuse","May impair ability to drive or operate heavy machinery","May exacerbate hypertension, tachyarrhythmias, and other cardiovascular conditions"] |
Loading safety data…
| Fetal Monitoring |
| If accidental exposure occurs during pregnancy, monitor fetal echocardiography for ductus arteriosus constriction, amniotic fluid index for oligohydramnios, and fetal renal function via ultrasound. Maternal monitoring for gastrointestinal bleeding and renal function. |
| Fertility Effects | Mefenamic acid may impair female fertility by inhibiting prostaglandin synthesis, potentially affecting ovulation and implantation. Reversible upon discontinuation. No data on male fertility. |